ããð¤ãð¦ @nachi05lego åãã¦ãã³ã¢ã°ã©ãã£åãã¦ãããã ãã©ããããããªãã¨ãâ¦â¦ãããªãã¨ã許ãããã®ãâ¦â¦ï¼ï¼ã¨ããæãã ã£ã ãããªãã¨ãâ¦â¦ï¼ï¼ 2025-10-07 15:56:25
ããð¤ãð¦ @nachi05lego åãã¦ãã³ã¢ã°ã©ãã£åãã¦ãããã ãã©ããããããªãã¨ãâ¦â¦ãããªãã¨ã許ãããã®ãâ¦â¦ï¼ï¼ã¨ããæãã ã£ã ãããªãã¨ãâ¦â¦ï¼ï¼ 2025-10-07 15:56:25
幹細èã¯ä½ãæ§æãããã¾ãã¾ãªç´°èã«ååããè½åãæã¡ãæå·ããä½çµç¹ã®åå¾©ã¨æå¸¸æ§ã®ç¶æã«å½¹ç«ã£ã¦ãã¾ãããå é½¢ã¨å ±ã«å¹¹ç´°èã¯åçè½åã失ã£ã¦ãã¾ãããããèåã®ä¸å ã¨ãªã£ã¦ãã¾ããæ°ãã«ä¸å½ç§å¦é¢ã¨é¦é½å»ç§å¤§å¦ã®ç ç©¶ãã¼ã ããé·å¯¿ã«é¢é£ããéºä¼åãåããã°ã©ã ããç¹æ®ãªå¹¹ç´°èã使ããé«é½¢ã®ã«ãã¯ã¤ã¶ã«ã«ã¿ãããèåã®å åãé転ãããå®é¨ã«æåãã¾ããã Senescence-resistant human mesenchymal progenitor cells counter aging in primates: Cell https://www.cell.com/cell/fulltext/S0092-8674(25)00571-9 Restoring youth: Scientists use engineered cells to restore vitality in pr
èèã®å¸å°ç¾æ£ã«è¦ãã¿ãé常ãªããèç§»æ¤ãæ»ãããéããªãã£ãKJã¨ãã赤ã¡ããã«ãéºä¼åæ²»çã«ããå¥è·¡ãããããããã¨å ±ããããã人éã®DNAã«å«ã¾ããæ°ååã®æåã®ãªãã®ããã£ãä¸ã¤ã®èª¤ã£ãæåãä¿®æ£ã§ããæè¡ã«ãã£ã¦ãç¾æ£ã®åå ã ã£ãéºä¼åã®å¤ç°ãæ£ããæ¸ãç´ããã®ã§ããã ãã®åæ¥ã®åå´è ã¨ãããã®ãããã¼ãã¼ã大å¦ã¨ããµãã¥ã¼ã»ããå·¥ç§å¤§å¦ï¼MITï¼ãå ±åéå¶ããããã¼ãç ç©¶æã®ææã§ãããåå¦è ã»ååçç©å¦è ã®ãã¤ã´ã£ããã»ãªã¥ã¦ï¼åå¦è¬ï¼ã ãä»èªãã¬ã¯ã¹ãã¬ã¹ãã話ãèããã
ã¢ã«ã¼ã³ãã³ã®ããããã£ç¼ç§ç ç©¶æï¼Benozzi Ophthalmological Instituteï¼ã§è¡ãããç ç©¶ã«ãã£ã¦ãèç¼ãæè¡ãèç¼é¡ã«é ¼ãããï¼æ¥ï¼åã®ç¹å¥ãªç¹ç¼è¬ã§æ¹åã§ããå¯è½æ§ããããã¨ã示ããã¾ããã ãã®ç¹ç¼è¬ã¯ãç³åï¼å ã調ç¯ããç®ã®ç©´ï¼ãå°ãããã¦è¿ãã®ç©ãããè¦ããããã«ããè¬ã¨ãç®ã®åºæ¿ãåãããè¬ãçµã¿åããã¦ä½ããã¦ãã¾ãã ç ç©¶ã§ã¯ãå®éã«ç®è¬ã使ã£ãå¤ãã®æ£è ããã§ããããï¼æéå¾ã«è¿ãã®æåãèªãè¦åã大ããæ¹åãããã®å¹æãï¼å¹´ä»¥ä¸ç¶ããã¨ã確èªããã¾ããã ãã®æ°ããç¹ç¼è¬ã®ç»å ´ã§ãèç¼é¡ã®é¢åããæè¡ã®ãªã¹ã¯ãé¿ãããä¸é«å¹´ã®äººãã¡ã®çæ´»ããä»å¾å¤§ããå¤ããããããã¾ããã æããã¦æ¬å½ã«ç®è¬ã ãã§èç¼ãæ¹åããæä»£ããã£ã¦æ¥ãã®ã§ããããï¼ ç ç©¶å 容ã®è©³ç´°ã¯2025å¹´9æ14æ¥ã«ã第43åESCRSãã«ã¦çºè¡¨ããã¾ããã Dose-Dep
Masayo Takahashi @masayomasayo æ°èãã¹ããã¤ããæ»æããè±ã¹ããã¤ããã¼ã ã«ãªã£ã彿(20年以ä¸å)è±ã¹ããã¤ãã§å ¨èº«ç«å·ã®ããã«ãã ããåä¾ã®ã¢ããã¼æ£è ãæã ç¼ç§ã«å ¥é¢ãã¦ãã¾ãããå¤åä¸è¬ã®æ¹ã¯ãããªç¶æ ç¥ããªãã§ããããçã¾ããã£ããçãã¦å¯ã¦ãéã«ç®ãå©ãã®ã§ç®ãç½å éãæ°´æ¶ä½è±è¼ãç¶²èå¥é¢ã§å¤±æããåä¾ããã¾ãããã®æªå¤¢ã¯ããããã¦ã»ããã 2025-08-14 15:31:46
ç°ä¸å¥ä¸ï¼ç°ä¸å ç @TNK_KNCH ææä½æã®ç¥ããªã³ã©ã¤ã³åå¼·ãµã¼ã¯ã«ãä¸ç¥å¡¾ï¼ããããã ãï¼ã塾é·ãè±èªæ°å¦ä¸çå²ç©çå«çæ¿çµç¾ç¤¾ï¼ç¾å ¬å ±ï¼ã®æå°æ´ãããèæ¸ã#ä¸çãåºããè±æèªè§£ãã#è±èª10é¡ããªã«ã·ãªã¼ãºããªã©ãæç¥çç«æåé«ç妿 ¡ã大éªå¤§å¦æå¦é¨ï¼è¥¿æ´å²å¦ï¼åæ¥ãåå¤å±å¤§å¦æå¦é¨ï¼è¨èªå¦ï¼ä¸éã質åç¸è«ã¯ä¸ç¥å¡¾ã«ã¦ãç«åªå 主義ðâ⬠note.com/tnk_knch/ ç°ä¸å¥ä¸ï¼ç°ä¸å ç @TNK_KNCH Twitterå²ä¸æé«ã¬ãã«ã®æ¬è³ªæ å ±ãæä¸ãã ä»ã¾ã§å¿é¿ãã¦ããã¸ã¸ã¤ç¨ã®ç®è¬ãæãåã£ã¦è©¦ãã¦ã¿ããããã³ãã®èª¿ç¯ãåçã«æ¹åããããè¦ãããè¦ãããï¼ãã¨å«ã³ãããªãã¬ãã«ã§ 2025-06-27 07:53:38
æ¥æ¬äººã®å¤§è ¸ããã®åæ°ã«ä¸é¨ã®è ¸å ç´°èãä½ãæ¯ç´ ãé¢ä¿ãã¦ããå¯è½æ§ãããã¨ããç ç©¶çµæãå½ç«ããç ç©¶ã»ã³ã¿ã¼ãªã©ã®ã°ã«ã¼ããã¾ã¨ãã¾ãããå¤§è ¸ãããäºé²ããè¬ã®éçºã«ã¤ãªãããã¨ãã¦ãã¾ãã å½ç«ããç ç©¶ã»ã³ã¿ã¼ç ç©¶æã®æ´ç°é¾å¼ åéé·ãã®ã°ã«ã¼ãã¯ãå½å ã§æãæ£è æ°ã®å¤ãå¤§è ¸ããã«ã¤ãã¦ãæ¥æ¬äºº28人ãå«ãä¸ç11ãå½ãããã1000äººã®æ£è ã®ããç´°èã詳ããè§£æãã¾ããã ãã®çµæããSBS88ãããID18ãã¨ããéºä¼åå¤ç°ãæ¥æ¬äººã®æ£è ã®åæ°ã«ããã14人ã§è¦ã¤ãã£ãã¨ãããã¨ã§ãã 䏿¹ããã®ã»ãã®å½ã§ã¯ããããå¤ç°ãããæ£è ã®å²åã¯1å²ãã2å²ç¨åº¦ã§ããã 2ã¤ã®éºä¼åå¤ç°ã¯ä¸é¨ã®è ¸å ç´°èãä½ãæ¯ç´ ãå¼ãèµ·ããã¦ããã¨ããã¦ãã¦ãã°ã«ã¼ãã¯æ¥æ¬äººã®å¤§è ¸ããã®åæ°ã«ãã®æ¯ç´ ãé¢ä¿ãã¦ããå¯è½æ§ãããã¨ãã¦ãã¾ãã ããã«ãæ£è ã®å¹´ä»£å¥ã«ã¿ãã¨2ã¤ã®éºä¼åå¤ç°ã¯50æ³æªæºã«å¤ãå¾
ç½è¡çã®ä¸ç¨®ã§ãããã¯ããã¡ã¼ã¸ï¼ä¸å¤®ï¼ããå¤§è ¸èï¼èµ¤ï¼ããæ¾åºãããæ¯ç´ ã«ãã£ã¦ç ´å£ãããæ§åãèµ°æ»åé»åé¡å¾®é¡ã§æ®å½±ããçè²ç»åãä¸é¨ã®å¤§è ¸èã¯ãç´°èã®DNAãå·ã¤ããæ¯ç´ ã³ãªãã¯ãã³ãæ¾åºããå¤§è ¸ããã®çºçãä¿ãå¯è½æ§ããããï¼MICROGRAPH BY STEVE GSCHMEISSNER, SCIENCE PHOTO LIBRARYï¼ è¥ãä¸ä»£ã®å¤§è ¸ããã®çºççãä¸ççã«å¢ãã¦ãããæè¿ã®ç ç©¶ã«ããã¨ãæ¥æ¬ã¯ãå¤§è ¸ããæ£è ã®å¢ãããã¼ã¹ããå¹´é·ã®ä¸ä»£ãã50æ³æªæºã®è¥ã人ã®ã»ããéãå½ã®ä¸ã¤ã ãå ·ä½çã«ä½ãè¥ãæ£è ã®æ¥å¢ãå¼ãèµ·ããã¦ããã®ãã«ã¤ãã¦ã¯ãããã¾ã§å¤ãã®ç§å¦è ãå»çå¾äºè ãé ãæ©ã¾ãã¦ãããï¼åèè¨äºï¼ãè¥ãä¸ä»£ã§å¤§è ¸ãããå¢å ãè¦éãã¦ã¯ãããªãå åã¨ã¯ãç ç©¶ãï¼ ããããå°éå®¶ã¯ä»¥åãããå¤§è ¸èãªã©ã®ç´°èãä½ãæ¯ç´ ã§ãããDNAãæå·ãããã³ãªãã¯ãã³ããé¢ãã£
å¬ã«ãªãã¨ãä¸çä¸ã§æ»äº¡çã䏿ããããã®ç¾è±¡ã¯ãå¬å£è¶ éæ»äº¡ï¼EWMï¼ãã¨å¼ã°ãã¦ãããï¼PHOTOGRAPH BY NORBERT ROSING, NAT GEO IMAGE COLLECTIONï¼ ã¯ãªã¹ãã¹ããã¬ã³ã¿ã¤ã³ãã¼ãªã©ãããå¬ã¯è¯ãããªå£ç¯ã ããå½ãè½ã¨ã人ãæãå¤ãå£ç¯ã§ããããããã¯ä¸ççã«è¦ãããè¬ã®å¤ãç¾è±¡ã§ããå¬å£è¶ éæ»äº¡ï¼EWMï¼ãã¨å¼ã°ãã¦ããã ä¾ãã°ãè±å½å®¶çµ±è¨å±ï¼ONSï¼ã«ããã°ãã¤ã³ã°ã©ã³ãã¨ã¦ã§ã¼ã«ãºã§ã¯2021å¹´ãã2022å¹´ã«ããã¦ã®å¬ï¼12ï½3æï¼ãæ»è æ°ãã»ãã®å£ç¯ã®å¹³åãã1ä¸3000人å¤ãã£ããç±³ç¾ç 対çã»ã³ã¿ã¼ï¼CDCï¼ã«ããã°ãç±³å½ã§ã¯2011ã2016å¹´ãå¬ã®æ»è æ°ã¯ã»ãã®å£ç¯ãã8ã12ï¼ å¤ãã£ãï¼ç·¨æ³¨ï¼æ¥æ¬ã§ã¯åçå´åçã®2014年人å£åæ çµ±è¨ã«åºã¥ãã12ï½3æã¯4ï½11æã«æ¯ã¹ã¦æ»è æ°ã17.5ï¼ å¤ãã¨ãã調æ»çµæãããï¼
ä»å¹´æåã®ããã°æ´æ°ã§ãã æ¨å¹´ã¯å¦ä¼æ´»åãªã©ãå¤ããã¦ãè¨ºçæ¥æ°ãä¾å¹´ããå°ãªããªã£ã¦ãã¾ãã¾ããããä¸ä¾¿ãããããç³ã訳ããã¾ããã§ããã ä»å¹´ã¯å°ãå¦è¡æ´»åãã»ã¼ããããã¨èãã¦ãã¾ããããã§ã«å¹¾ã¤ãä¾é ¼ãèãè¾¼ãã§ãããä»å¹´ãå¿ãããªãããã§ãããã®å¹´é½¢ã«ãªãã¨ãç·è«çãªè¬æ¼ãåãã¾ã¨ãå½¹ã®ä»äºãå¢ãã¦ãã¦ã客観çãã¤å ¬å¹³ãªãã¸ã·ã§ã³ã§å¥½ããªããã«çºè¨ã§ããã¨è¯ããªã¨æã£ã¦ãã¾ãã ã§ã¯å¹´ã®åãã¨ãããã¨ã§ãæ¨ä»ã®ç¾å®¹å»çåé¡ã«ã¤ãã¦ç§å人ã®èããæ¸ãã¾ãã ããæ°å¹´ãç¾å®¹å»çæ¥çã¯åå ¥å»å¸«ãå¢å ãã䏿°ã«é£½åãã¦ãã¾ãããããããæ£è ãµã¤ãã®éè¦ã¯ã¾ã ã¾ã å¢ãã¦ããã¨ã¯æãã¾ããããã åç´ã«ç¾å®¹å»çããã¸ãã¹çã«å®è·µãã¦ã䏿ããããªãæä»£ã«ãªãã¤ã¤ããã¾ããæéã®å·®ãåºããªããã¨ãå¤ãã¬ã¼ã¶ã¼è±æ¯ã§ã¯ä¾¡æ ¼ç«¶äºã¨ãªããæ¨å¹´å¤§æãã§ã¼ã³ã¯ãªããã¯ãåç£ããã®ã¯è¨æ¶ã«æ°ããã¨ããã§ã
ç¾ä»£ç¤¾ä¼ã«ããã¦ãå¹´é½¢ãçºéã«æ¯ã¹ã¦æ³¨æåãè¶³ããªããè¡åçã§è½ã¡çãããªããªã©ã®ç¹å¾´ãçç¶ã¨ããæ³¨ææ¬ å¦å¤åç(ADHD)ã¯ãç¥çµçºéçãçºéé害ã¨ã¿ãªããã¦ãã¾ããããããADHDã®ç§å¦ççè§£ãé²ãã«ã¤ãã¦ãå°éå®¶ã¯ãADHDãé害ã¨ã¿ãªãã¹ããªã®ããã«ã¤ãã¦çåãæ±ãã¦ãã¾ãã Researchers are questioning if ADHD should be seen as a disorder https://www.economist.com/science-and-technology/2024/10/30/researchers-are-questioning-if-adhd-should-be-seen-as-a-disorder è¿å¹´ãADHDã®è¨ºææ°ã¯å¤ãã®å½ã§æ¥éã«å¢å ãã¦ãããã¢ã¡ãªã«ã®2ä¸6000ã®è¨ºçæãç é¢ã§ADHDã¨ã®è¨ºæãåããäººã®æ°ã¯2020å¹´
ï¼ï¼£ï¼®ï¼®ï¼Â ãã¬ã¤ã¯ãã³ã¹ã代表ããåãã®ä¸ã¤ããããã¹ãã³ã身ä½ã«äºæãã¬å½±é¿ãåã¼ããã¨ãæããã«ãªã£ãããã³ãã¼ã¯ã®ç ç©¶è ããï¼ï¼æ¥ãé¢é£ããçä¾å ±åãå ¬éããã ãã¬ã¤ã¯ãã³ã¹ã¯ãã¬ã¤ãã³ã®åç§°ã§ãä»å¤ã®ããªäºè¼ªã®æ¡ç¨ç¨®ç®ã«ããªã£ã¦ããããã³ãµã¼ã¯é«ã身ä½è½åã¨ãã³ã¹ã®åµé æ§ã§è¦³å®¢ãé äºããããããã«ã¯èº«ä½çãªãªã¹ã¯ãä»ãã¦åããææ ¹ç®¡çå群ãã¯ããã¨ããç¥çµé害ãããã¦ãã³ãµã¼ã®éã§ããããã¹ãã³ã»ãã¼ã«ãã¨ãã¦ç¥ãããçç¶ãªã©ãããã«è©²å½ãããå¾è ã¯ãããã¹ãã³ã®å¤ç¨ãé ç®ã«æªå½±é¿ãããããç¶æ ãæãã é常ã¯é 髪ãæãè½ã¡ããã¨ã«å§ã¾ããå ´åã«ãã£ã¦ã¯é é é¨ã大ããè «ããã¨ãã£ãçç¶ãåºãã ï¼ï¼æ¥ã«å»å¦èªï¼¢ï¼ï¼ªã«æ²è¼ãããçä¾å ±åã§ã¯ããã¬ã¤ã¯ãã³ã¹æ´ï¼ï¼å¹´è¿ãã®ï¼ï¼ä»£ååã®ç·æ§ããè¯æ§è «çï¼ãã ããï¼ã®æ²»çãåãããè «çã¯åãç´ï¼ï¼ï¼ã»ã³ã以ä¸ã®å¤§ããã«ãªã£ã¦ããã ãã
é廿°åå¹´ã§ä¸çã®é£èçç£éã¯æ¥å¢ãã¦ãã¾ãããèã®æåéãå¢ããã¨2åç³å°¿ç ã®ãªã¹ã¯ãä¸ããã¨ããææãããã¾ããä¸çä¸ã«ä½ãç´200ä¸äººã®ãã¼ã¿ãåæããæ°ããªç ç©¶ã§ã¯ããã ãªã©ã®å å·¥èã赤身èãé£ã¹ãã¨2åç³å°¿ç ã®ãªã¹ã¯ãé«ã¾ãå¯è½æ§ã示åããã¾ããã Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100â000 incident cases from 31 cohorts in 20 countries - The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PI
å¢ç°ã¯å ã ãå¸è²©ã®ãããã³ãã¼ãã½ã¼ã¹ãå³ãæ¿ããããããã¹ã¿äºäººåãä¸åº¦è¯ããã¨ãè¨ããªãããã«é£ãç³å°¿ç 寸åã¾ã§è¡ã£ã¦ãã馬鹿ãªããã§ããã é½¢30ãéããå°¿ã«å¤ãªæ³¡ãç«ã¡å§ãã¦ããããããã¯ã¤ããã¨ä¸å¿µçºèµ·ãã30kgç©ããéå»ãæã¤ã ãã®ã¨ããå¥åº·çã«ç©ããããã«è¡ç³å¤ã¨ã¤ã³ã¹ãªã³ã®é¢ä¿ã«ã¤ãã¦ã¯å¤§ååå¼·ããã®ã§ãããã«é£ãæ°çµ¶ãã«é¢ããéãªè¨èãè¸ããã¡ãªæ¨ä»ãèªåã®ç¥ãéãã®ç¥èããã®ã¿ã¤ãã³ã°ã§ã¾ã¨ãã¦ããã ééã£ã¦ãããã¨ãææ§ãªé¨åããããç¥ããªãããããã¯æ¬è·ã®å»ã¯ã©ãããã¯ã¦ãã«ãããã®ã§é å¼µã£ã¦è£è¶³ãã¦ããã ãããã ããããè¡ç³å¤ã¯ä½æ ä¸ããã®ããããããæã ç´ äººãåéãããã¡ãªã¨ããã¨ãã¦ããè¡ç³å¤ã使 ä¸ããã®ããã«ã¤ãã¦ã®ã¡ã«ããºã ãã®ãã®ãããã è¡ç³ã¨ã¯ãé£äºã§æåããç³ãç´æ¥åºã¦ãããã®ã§ã¯ãªãã é£å¾è¡ç³å¤ã¨ãããã®ã¯30åãããã«ä¸ããå§ããã
åèç®¡æ©æééï¼premature closure of ductus arteriosusï¼PCDAï¼ã®åå ã¨ãã¦æ¯ä½ã¸ã®éã¹ããã¤ãæ§æççè¬ï¼non-steroidal anti- inflammatory drugsï¼NSAIDsï¼ãç¥ããã¦ãããï¼è¿å¹´ããªãã§ãã¼ã«ãåå ã¨ãªããã¨ãå ±åããã¦ããï¼ããªãã§ãã¼ã«å«æé£²æãåå ã¨æãããPCDAãçããã1ä¾ãçµé¨ããï¼çä¾ã¯å¨è37é±3æ¥ï¼2,730gã§åºçããä¸çµ¨æ¯èäºç¾èåè第2åï¼çå¾2æéããé ¸ç´ åä¸è¯ãèªãï¼ãã®å¾ãé ¸ç´ éè¦ãç¶ãããæ¥é½¢1ã«NICUã«å ¥å®¤ããï¼è¸é¨Xç·ï¼12èªå°å¿é»å³ã§å³å®¤è¥å¤§ãèªãããï¼å¿ã¨ã³ã¼å³ã§ã¯åè管ééï¼å¿å®¤ä¸éã®å¹³å¦åï¼å¿æ¿éã®å³å·¦ç絡ãèªãããï¼PCDAãçãããï¼å¦å¨ ä¸ã«NSAIDsã®æç¨ã¯ãªãã£ãï¼ãããè¶ã¨ã«ã¤ãã¹ãã£ã¼ã飿¥é£²ç¨ãã¦ãããã¨ã夿ãï¼PCDAã®åå ã¨ãã¦ãããã«å«
é³ã¨å ã§æ²»çã§ãã¾ãã å®ã¯ããã¾ã§ã®ç ç©¶ã§ã40Hzã®é³ã¨å ãã¢ã«ããã¤ãã¼ç ã«ã¿ãããã¢ããã¤ãβãè³å ããæ¸ãã广ãæã¤ãã¨ãç¥ããã¦ãã¾ããã ãã ããªããããªãã®ã§ã¢ã«ããã¤ãã¼ç ã«å¯¾å¦ã§ããã®ããè³å ã§ã©ããªã¡ã«ããºã ãåãã¦ããã®ãã¯ããããã£ã¦ãã¾ããã§ããã ãããä»åãç±³å½ã®MITï¼ããµãã¥ã¼ã»ããå·¥ç§å¤§å¦ï¼ã§è¡ããããã¦ã¹ç ç©¶ããæ¯ç§40åï¼40Hzï¼ã®é³ã¨å ã®åºæ¿ã«ãã£ã¦ãæå®³ãªã¢ããã¤ãβã¿ã³ãã¯è³ªãè³å ããæ´ãæµãã¡ã«ããºã ã«ã¤ãã¦æããã«ãã¾ããã ä¸ä½ã©ããã¦é³ã¨å ã ãã§ãè³å ã®æå®³ç©è³ªã¯æé¤ãããã®ã§ããããï¼ ç ç©¶å 容ã®è©³ç´°ã¯2024å¹´2æ28æ¥ã«ãNatureãã«æ²è¼ããã¾ããã
ç¹å¹è¬ããªãå ´åããã®ãã¨èªä½ã¸ã®ä¸æºããã£ã¦ãæ¤è¨¼ãä¸ååãªè¬ã§ãã£ã¦ããå¹ããã¨ããã¦ã¯ãµãããã¨ã飲ãã§ã¿ãããããã¨æããã¡ã ããããå ç§å»ã®ååå®ããã¯ã广ã誤èªãããã¨ã¯ãããããæ¤è¨¼ä¸ååãªè¬ã«ã¯ãªã¹ã¯ãããããã夿ã¯ä¿çãã¹ãã ãã¨ããââã 广ã«ä¹ããè¬ãåå¨ããçç± ç¾å¨ãè¬ãæ¿èªãããã¾ã§ã«ã¯é·æéããã¦æ¤è¨¼ãè¡ããã¾ããæ°è¬åè£ã®ç©è³ªãæ¿èªã«è³ã確çã¯æ°ä¸åã®1ã¨ãããããã»ã©ã§ãã åºç¤ç ç©¶ãåç©å®é¨ã§ä¸å®ã®å®å ¨æ§ã广ãæå¾ ã§ããæ°è¬åè£ã®ç©è³ªãçµãè¾¼ãã ã®ã¡ãé常ã¯å°æ°ã®å¥åº·ãªæäººã対象ã«å®å ¨æ§ãè¬ç©åæ ãè©ä¾¡ãã第1ç¸è©¦é¨ãæ¯è¼çå°æ°ã®æ£è ããã対象ã«å®å ¨æ§ã¨æå¹æ§ãè©ä¾¡ãã第2ç¸è©¦é¨ãå¤ãã®æ£è ããã対象ã«ãã第3ç¸è©¦é¨ãçµã¦ãååãªå®å ¨æ§ã¨æå¹æ§ã確èªã§ããè¬ã ããæ¿èªããã¾ããå¸è²©å¾èª¿æ»ã¨ãã£ã¦æ¿èªã»çºå£²ãããå¾ãæ¤è¨¼ã¯ç¶ãã¾ãããã£ããã¯ä¿éºé©
ç ç©¶ã¯ç¶ãã¦ããããã§ãã ä¸å½ã®å京工ç§å¤§å¦ã§è¡ãããç ç©¶ã«ãã£ã¦ãã»ã³ã¶ã³ã³ã¦ããå¾ãããã³ããã¦ã¤ã«ã¹æ ªãGX P2Vãããã¦ã¹ã«ææãããã¨ãããé常ã«å¼·ãæ¯æ§ãçºæ®ããææå¾8æ¥ã®æ®µéã§è´æ»ç100%ã«éããã¨å ±åããã¾ããã ç ç©¶ã«ä½¿ããããã¦ã¹ãã¡ã¯æ»ã¬2æ¥åï¼6æ¥ç®ï¼ã«è³ã¸ã®ææãåçã«å¢åããæ»ã¬1æ¥åï¼7æ¥ç®ï¼ã«ã¯ç®ãç½ããªãã¨ããå¥å¦ãªå ±éç¹ãã¿ããã¾ããã ã³ããé¢é£ã¦ã¤ã«ã¹ã使ã£ããã¦ã¹å®é¨ã«ããã¦ãè´æ»çã100ï¼ ã«éããã®ã¯ä»åã®ç ç©¶ãã¯ããã¦ã§ãã ãã å®é¨ã«ä½¿ããããã¦ã¹ã¯ã¦ã¤ã«ã¹ææãèµ·ããé¨ä½ãACE2ãããããåãããã¦ããã人éã«å¯¾ããæ½å¨çãªå½±é¿ãæ¸å¿µããã¦ãã¾ãã ç ç©¶å 容ã®è©³ç´°ã¯2024å¹´1æ4æ¥ã«ãã¬ããªã³ããµã¼ãã¼ã§ãããbioRxivãã«ã¦å ¬éããã¾ããã
æå¹å»ç§å¤§ãç·åå»çã¡ã¼ã«ã¼ã®ãããï¼å¤§éªï¼ã¨å ±åã§éçºãããä¸çåã®è髿å·ã®åçå»çæ²»çè¬ãã¹ããã©ãã¯ããï¼ï¼ï¼ï¼å¹´æ«ã«å½ã®è£½é è²©å£²ã®æ¿èªãå¾ã¦ããï¼å¹´ããã£ãããã®éãæä¸ãè¡ãæ½è¨ã¯å ¨å½ã«åºãããç´ï¼ï¼ï¼äººãä¿éºè¨ºçã§æ²»çãåããããã¤ã¦è髿å·ã®æ²»çã¯æè¡ããªãããªä»¥å¤ã«é¸æè¢ããªãã£ãããåæµ·éã»æå¹ã§çã¾ããç»æçãªæ²»çè¬ã®ç»å ´ã§ãå·ã¤ããç¥çµãã®ãã®ãåçããããã¨ãå¯è½ã«ãªã£ããå¯ããããæè¶³ãã¾ã²ããæ£è ããèµ·ãä¸ãã£ããæè¶³ãåãããã«ãªããæ¥å¸¸çæ´»ãåãæ»ãã¦ãããï¼å ±éã»ã³ã¿ã¼ã岩æ¬é²ï¼ ã幸ããæé«ã§ãããï¼ï¼å¹´ï¼ï¼æï¼æ¥ãç¦å¶åæ¶ï¼ãµããã¾ã»ãããï¼ããï¼ï¼ï¼ï¼ï¼å±±å£å¸ï¼ãæå»å¤§ç é¢ã®çé¢åã§æºé¢ã«ç¬ã¿ãæµ®ãã¹ããåå¹´è¿ãæ²»çã¨ãªãããªãçµããéé¢ãè¿ãããï¼æ¬ã®è¶³ã§ä¸æ©ãã¤åã¸ã¨è¸ã¿åºããã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}